Ligazid 5

Generic

Linagliptin

 

Indications

Linagliptin is used to treat type 2 diabetes mellitus in people and enhance glycaemic control.

As monotherapy: in individuals who are unable to manage their blood sugar levels with diet and exercise alone and for whom metformin is either ineffective or contraindicated owing to renal impairment.

When diet and exercise plus metformin alone do not provide adequate glycaemic control, use in combination with a sulphonylurea and metformin. When diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control, use in combination with a sulphonylurea and metformin.

 

Pharmacology

Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Linagliptin stimulates the release of insulin from pancreatic beta () cells in a glucose-dependent manner while reducing the production of glucagon from pancreatic alpha () cells in the blood, increasing the concentrations of active incretin hormones.

 

Dosage & Administration

Once a day, take 5 mg of linagliptin. If linagliptin is added to metformin, the metformin dose should be maintained and linagliptin should be given at the same time. When combined with a sulphonylurea, a lower sulphonylurea dosage may be explored to minimize the risk of hypoglycemia.

There is no need to modify the dosage in patients with renal impairment. Linagliptin can be taken at any time, with or without food.

 

Interaction

Linagliptin is a mild competitive and weak to moderate mechanism-based inhibitor of the CYP3A4 isozyme, however it has no effect on the other CYP isozymes. The risk of clinically significant interactions with other medical products is minimal, and linagliptin had no clinically significant influence on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, or digoxin in clinical trials.

 

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

 

Side Effect

When metformin and sulfonylurea are used together, hypoglycemia, nasopharyngitis, cough, and pancreatitis might occur.

 

Pregnancy & Lactation

Category B pregnancy. In pregnant women, there are no appropriate and well-controlled trials. As a result, Linagliptin tablets should only be taken during pregnancy if absolutely necessary. It is unknown whether Linagliptin is excreted in breast milk.

 

Precautions & Warnings

Hypersensitivity to the active ingredient or any excipient.

 

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

 

Storage Conditions

Keep away from light and heat in a dry area. Keep out of children's reach.

 

Pharmaceutical Name

Eskayef Pharmaceuticals Ltd.